drugset / Trial / NCT00461565

FDA Phase IV - Commitment - Retinal Function Study

NCT00461565

Phase 4 Completed 63 enrolled Bayer GlaxoSmithKline · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

Vardenafil (Levitra) and Sildenafil (Viagra) are drugs that are marketed for use in patients with erectile dysfunction. The purpose of this study is to find out if there are any changes in the eye after taking at least 15 doses of Vardenafil and after two doses of Sildenafil. This is a double-blind study, which means that neither you nor the study doctor will know which treatment you are receiving. If you qualify for the study, you will receive:- Vardenafil 20 mg twice per week (Monday and Thursday) for a maximum of 8 weeks. There will be two times when this occurs during the study.- Sildenafil 200 mg/day for two days. There will be two times when this occurs during the study. - Placebo (a pill that looks like vardenafil or sildenafil but has no active ingredient).

Timeline

Start
2005-02
Primary completion
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sildenafil Unknown 200 mg Oral
Subject Vardenafil Small molecule 20 mg Oral

Indications

No indication recorded.